Trial Profile
Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir Compared to Standard of Care in Hospitalized Subjects With COVID-19
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary)
- Indications COVID 2019 infections
- Focus Proof of concept; Therapeutic Use
- Sponsors FujiFilm Pharmaceuticals USA
- 20 Jul 2021 Status changed from active, no longer recruiting to completed.
- 25 May 2021 Planned End Date changed from 1 May 2021 to 1 Jul 2021.
- 04 Feb 2021 Planned End Date changed from 1 Nov 2020 to 1 May 2021.